Results
1
-
10
of
76
<
1
2
3
...
7
8
>
Min SH; Goldman ID; Zhao R.
Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.
,
Cancer chemotherapy and pharmacology
[PubMed: 17594092]
[DOI: 10.1007/s00280-007-0539-z]
Hata A; Katakami N; Hattori Y; Otsuka K; Nishiyama A; Tsubouchi K; Kaneda T; Yoshioka H; Morita S; Negoro S; Tanaka K; Fujita S; Kotani Y; Nishimura T; Imamura F; Yokota S; Satouchi M; Monden K.
Pemetrexed monotherapy for chemo-na?ve elderly (aged ?80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
,
Cancer chemotherapy and pharmacology
[PubMed: 28280972]
[DOI: 10.1007/s00280-017-3259-z]
Park S; Kim HJ; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Choi SH; Rho JK; Lee JC.
Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.
,
BMC cancer
[PubMed: 27388008]
[DOI: 10.1186/s12885-016-2457-0]
Kucharczyk T; Krawczyk P; Powr?zek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wr?blewska M; Winiarczyk K; Krzakowski M; Milanowski J.
The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
,
Pathology oncology research : POR
[PubMed: 26277606]
[DOI: 10.1007/s12253-015-9966-z]
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S.
Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
,
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PubMed: 26220094]
[DOI: 10.1007/s12094-015-1359-y]
Daga H; Takeda K; Okada H; Tanaka T; Kaiser R; Nakagawa K; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A.
Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
,
Cancer chemotherapy and pharmacology
[PubMed: 26560486]
[DOI: 10.1007/s00280-015-2896-3]
Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S.
A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
,
Medical oncology (Northwood, London, England)
[PubMed: 26168982]
[DOI: 10.1007/s12032-015-0660-5]
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K.
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
,
Cancer chemotherapy and pharmacology
[PubMed: 26259641]
[DOI: 10.1007/s00280-015-2843-3]
Hata A; Katakami N; Fujita S; Morita S; Urata Y; Negoro S; Nanjo S; Takeshita J; Tanaka K; Kaneda T; Nishiyama A; Nishimura T; Nakagawa A; Otsuka K.
A phase II study of pemetrexed monotherapy in chemo-na?ve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).
,
Cancer chemotherapy and pharmacology
[PubMed: 25925001]
[DOI: 10.1007/s00280-015-2755-2]
Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H.
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
,
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
[PubMed: 25417899]
[DOI: 10.1007/s13277-014-2862-4]
<
1
2
3
...
7
8
>